Bedrijfsoverzicht
Travere Therapeutics, Inc. is a biopharmaceutical enterprise dedicated to the identification, development, and delivery of advanced therapies for patients suffering from rare kidney and metabolic diseases within the United States. The company operates within the Healthcare sector, specifically classified under the Biotechnology industry, which typically involves high levels of research and development expenditure to bring novel treatments to market. As of the latest reporting period, the organization employs a workforce of 497 individuals and maintains a total market capitalization of $2.67 billion. With an annual revenue of $490.73 million, these financial figures indicate that Travere has established a significant commercial footprint, yet the market valuation suggests the market places a premium on its pipeline assets rather than current profitability. The disparity between the substantial market cap and the negative net income highlights that the company's valuation is driven primarily by future growth potential and intellectual property value rather than historical earnings performance.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $490.73 million, while posting a net income loss of $-50,261,000 and an EBITDA of $-2,081,000. The substantial gap between the positive revenue of $490.73 million and the negative net income reveals a cost structure characterized by high operating expenses, likely driven by clinical trial costs and research activities common in early-stage biotechnology. Free cash flow stands at $-38,295,500, indicating that the company is currently burning cash to fund its operations and development efforts, which limits immediate financial flexibility but is a typical strategy for companies prioritizing long-term product launches over short-term liquidity preservation. Profitability analysis shows a gross margin of 55.9%, suggesting efficient production and sales costs relative to revenue, whereas the operating margin of -25.0% and profit margin of -5.2% reflect the significant overhead costs required to sustain a biopharmaceutical business before achieving break-even. The balance sheet presents a leveraged position with total debt of $328.73 million against cash reserves of $322.80 million, resulting in a debt-to-equity ratio of 286.28, which underscores the company's reliance on equity financing and its high financial leverage relative to shareholder equity. Despite the high debt load, the current ratio of 2.74 indicates strong short-term liquidity, suggesting the company possesses sufficient current assets to cover its short-term liabilities without immediate distress. Return metrics further illustrate the financial reality of the sector, with a return on equity of -57.8% and a return on assets of -6.5%, revealing that management effectiveness is currently measured by the ability to preserve capital and advance the pipeline rather than generating shareholder returns through dividends or profit distribution.
Waarderingsbeoordeling
Valuation metrics for Travere Therapeutics present a complex picture, as the P/E Ratio (TTM) is listed as N/A due to the lack of positive earnings, while the forward P/E stands at 6.97, implying that the market expects a significant turnaround in earnings trajectory to justify the current valuation multiple. The price-to-book ratio is elevated at 22.93, indicating that the market assigns a substantial premium to the company's assets, valuing the firm at more than 22 times its book value, which reflects confidence in the intangible value of its drug candidates. Alternative valuation measures such as the price-to-sales ratio of 5.44 and the EV/EBITDA of -1286.52 further suggest that traditional earnings-based metrics are insufficient for assessing the company, as the negative EV/EBITDA confirms that valuation is based on revenue generation and asset potential rather than current profitability. The stock price has fluctuated significantly within a 52-week range bounded by a high of $42.13 and a low of $13.88, meaning the current trading price sits somewhere within this wide band, reflecting the high volatility typical of biotechnology stocks awaiting clinical milestones. The beta of 0.87 indicates that the stock's price volatility is slightly lower than the broader market, suggesting that while the stock can move independently, it generally tracks market movements with a slightly dampened intensity compared to a beta of 1.0.
Growth & Income
Revenue growth has accelerated dramatically with a year-over-year increase of 73.4%, while earnings growth is listed as N/A due to the company's continued losses, indicating that the expansion of revenue is not yet translating into bottom-line profitability. Because the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders, which is consistent with its stage of development where capital is retained to fund research and commercialization efforts. The absence of a dividend payout ratio means the company reinvests all available resources, including its cash reserves, directly into operational growth and clinical development rather than providing regular income to investors. The overall growth and income profile is defined by rapid top-line expansion coupled with a lack of current income generation, positioning Travere as a pure-play growth asset that relies on future regulatory approvals and market uptake to eventually convert revenue into sustainable earnings and potentially future dividends.